Preventing antimalarial drug resistance with triple artemisinin-based combination therapies.
Preventing antimalarial drug resistance with triple artemisinin-based combination therapies.
复制标题
以青蒿素为基础的三联疗法预防抗疟药物耐药性。
DOI：
10.1038/s41467-023-39914-3
复制
发表时间：
2023-07-29
影响因子：
16.6
通讯作者：
Aguas, Ricardo
中科院分区：
文献类型：
--
作者：
Nguyen, Tran Dang;Gao, Bo;Amaratunga, Chanaki;Dhorda, Mehul;Tran, Thu Nguyen-Anh;White, Nicholas J.;Dondorp, Arjen M.;Boni, Maciej F.;Aguas, Ricardo
青蒿素及其伙伴药物耐药性的不断增加威胁着全球疟疾控制和消灭工作。将青蒿素衍生物与两种伙伴药物联合收割机结合的青蒿素三联疗法在临床试验中，包括在耐多药疟疾领域，是有效的，耐受性良好。早期采用TACT是否可以延迟抗疟药物耐药性的出现和传播是一个至关重要的问题。使用两个独立的基于个体的恶性疟原虫流行病学和进化模型，我们评估了与继续使用ACT相比，引入青蒿琥酯-甲氟喹-哌喹或蒿甲醚-苯芴醇-阿莫地喹是否会导致较低的长期青蒿素耐药性水平和治疗失败率。我们表明，TACT的引入可以显着延迟青蒿素耐药性和治疗失败的出现和传播，延长当前抗疟药物的有效治疗寿命，并提高消除疟疾的机会。我们的结论是，在出现青蒿素耐药性的地区，决策者应考虑立即采用TACT。初步研究表明，青蒿素三联疗法对治疗疟疾有很高的疗效。在这里，作者使用数学模型来评估与一线疗法相比，这些疗法是否也可以延迟抗疟药耐药性的出现和传播。
Increasing levels of artemisinin and partner drug resistance threaten malaria control and elimination globally. Triple artemisinin-based combination therapies (TACTs) which combine artemisinin derivatives with two partner drugs are efficacious and well tolerated in clinical trials, including in areas of multidrug-resistant malaria. Whether early TACT adoption could delay the emergence and spread of antimalarial drug resistance is a question of vital importance. Using two independent individual-based models of Plasmodium falciparum epidemiology and evolution, we evaluated whether introduction of either artesunate-mefloquine-piperaquine or artemether-lumefantrine-amodiaquine resulted in lower long-term artemisinin-resistance levels and treatment failure rates compared with continued ACT use. We show that introduction of TACTs could significantly delay the emergence and spread of artemisinin resistance and treatment failure, extending the useful therapeutic life of current antimalarial drugs, and improving the chances of malaria elimination. We conclude that immediate introduction of TACTs should be considered by policy makers in areas of emerging artemisinin resistance. Triple artemisinin-based combination therapies have shown high efficacy for treatment of malaria in preliminary studies. Here, the authors use mathematical modelling to assess whether these therapies could also delay the emergence and spread of antimalarial drug resistance when compared against frontline therapies.
登录
查看更多内容
影响因子：
6.7
作者：
Miotto O;Sekihara M;Tachibana SI;Yamauchi M;Pearson RD;Amato R;Gonçalves S;Mehra S;Noviyanti R;Marfurt J;Auburn S;Price RN;Mueller I;Ikeda M;Mori T;Hirai M;Tavul L;Hetzel MW;Laman M;Barry AE;Ringwald P;Ohashi J;Hombhanje F;Kwiatkowski DP;Mita T
通讯作者：
Mita T
影响因子：
7.7
作者：
Mathieu, Luana C.;Cox, Horace;Musset, Lise
通讯作者：
Musset, Lise
DOI：
10.3389/fepid.2022.1041896
发表时间：
2022-01-01
期刊：
Frontiers in epidemiology
影响因子：
--
作者：
Boni, Maciej F
通讯作者：
Boni, Maciej F
DOI：
10.1016/s2214-109x(17)30076-1
发表时间：
2017-04
期刊：
The Lancet. Global health
影响因子：
--
作者：
Bennett A;Bisanzio D;Yukich JO;Mappin B;Fergus CA;Lynch M;Cibulskis RE;Bhatt S;Weiss DJ;Cameron E;Gething PW;Eisele TP
通讯作者：
Eisele TP
DOI：
10.1093/cid/cix1122
发表时间：
2018-06-01
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Mombo-Ngoma G;Remppis J;Sievers M;Zoleko Manego R;Endamne L;Kabwende L;Veletzky L;Nguyen TT;Groger M;Lötsch F;Mischlinger J;Flohr L;Kim J;Cattaneo C;Hutchinson D;Duparc S;Moehrle J;Velavan TP;Lell B;Ramharter M;Adegnika AA;Mordmüller B;Kremsner PG
通讯作者：
Kremsner PG